Contact your Congressional Representatives to co-sponsor the Clinical Treatment Act (HR913)

This Weekly’s Hot Topics

  • California Cancer PAC 2019 Legislative Update California News
  • Contact your Congressional Representativesto co-sponsor the Clinical Treatment Act (HR913) National News
  • CMS will not be issuing final NCD on CAR T-cell therapy for cancer. CMS News

 

MOASC & ANCO California Cancer PAC 2019 Legislative Update: Both houses held their Appropriations Suspense hearings last week. We are pleased to report that the bill that will require the Board of Pharmacy to create the Cancer Medication Advisory Task Force passed out of Committee on a unanimous vote. To read more click here and go to California News.

ANCO, MOASC, and ASCO call on all members to contact their Congressional Representatives to as ask them to become co-sponsors of the Clinical Treatment Act (HR913) that would guarantee overage of routine care costs of clinical trial participation for Medicaid enrollees with life-threatening conditions. To read more click here and go to National News.

National Coverage Analyses. Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers CMS will not be issuing a final National Coverage Determination on CAR T-cell therapy for cancer. The agency didn’t give any reason for the delay in finalizing the proposal that was released in February, but a decision is forthcoming. To read more click here and go to CMS News.

The Community Oncology Alliance is launching a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen abuse of patients with cancer is not lost in policy deliberations in Washington. For the past several months the California Oncology Weekly, under MOASC News, has been asking for oncology practices to please provide their “horror” stories of the obstruction to timely access to oncology care. To read more click here and go to Affiliate News.

To read the complete California Oncology Weekly Newsletter, click on the date below.

May 21, 2019

This Weekly’s Hot Topics

  • Trump administration to require drug companies to include price of drug in television advertisements. National News
  • Tomorrow is last day to review and dispute Open Payments. CMS News
  • ASCO invites your review of clinical guidelines, by May 16. Affiliate Association News

 

Gov. Gavin Newsom’s administration reversed course on his plan to divert public health dollars from several counties to help provide health coverage to young adults who are in the country illegally. The administration considered the concerns of Sacramento, Placer, Santa Barbara and Stanislaus counties, which had warned that the governor’s plan would compromise their ability to cope with surging rates of sexually transmitted diseases and, in some cases, measles outbreaks. To read more click here and go to California News.

The drugs included everything from tablets and capsules to creams and ointments to treat conditions including cancer and more. U.S. states filed a lawsuit accusing Teva Pharmaceuticals USA Inc of orchestrating a sweeping scheme with other drug companies to inflate drug prices – sometimes by more than 1,000%, and stifle competition for generic drugs, state prosecutors said on Saturday. To read more click here and go to National News.

Tomorrow, May 15, is last day for U.S. physicians to review and dispute Open Payments data before it is made public on June 30. Review of the data is voluntary, but strongly encouraged to help improve the accuracy of the reported data. To read more click here and go to CMS News.

Through May 16, ASCO invites key stakeholders to critically review and identify any errors in draft clinical practice guidelines prior to their finalization and publication. One draft clinical practice guideline or update is now open for comment–germline and somatic tumor testing in epithelial ovarian cancer. To read more click here and go to Afilliate Association News.

To read the complete California Oncology Weekly Newsletter, click on the date below.

May 14, 2019